← Leaderboards
Sergei Doulatov
Boston Children'S Hospital
$9,365,892
Attributed
$13,336,948
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2014–25$5M$3.8M$2.5M$1.3M$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,336,948 · 7
By mechanism
R01$4,918,347 · 2
RC2$4,661,966 · 1
DP2$2,332,500 · 1
R00$746,999 · 1
R21$413,750 · 1
K99$263,386 · 1
Top collaborators
- Robert K Bradley6 shared
- Marie Bleakley3 shared
Most similar at Boston Children'S Hospital
Same institution · by research overlap
- Ben Adam Croker$3,608,646
- Vijay Ganesh Sankaran$14,100,782
Others in their field
Top investigators on “Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$220,248,453
- David Heimbrook · Leidos Biomedical Research, Inc.$161,931,307
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$73,044,559
- Tatiana M. Foroud · Indiana Univ-Purdue Univ At Indianapolis$70,591,644
- Michelle M Le Beau · University Of Chicago$70,506,423
Research focus
Stem CellsCellsHematopoietic Stem CellsGenesInduced Pluripotent Stem CellDysmyelopoietic SyndromesHematological DiseaseHematopoiesisBloodBiologyIn VivoMutationTranscription FactorMolecularSomatic MutationProgramsTargeted TreatmentImpairmentSpecific Qualifier ValueClonal ExpansionCell LineDisease ModelProgenitorProduction
Grant awards (20)
Development of Innovative Resources to Advance MDS Research$1,574,993
RC2 · FY2025 · DK
Functional and molecular consequences of SF3B1 mutations in human hematopoietic stem cells$719,314
R01 · FY2025 · HL · contact PI
The role of lamin B1 in normal and myelodysplastic hematopoiesis$508,817
R01 · FY2025 · HL · contact PI
Development of Innovative Resources to Advance MDS Research$1,511,993
RC2 · FY2024 · DK
The role of lamin B1 in normal and myelodysplastic hematopoiesis$555,935
R01 · FY2024 · HL · contact PI
Development of Innovative Resources to Advance MDS Research$1,574,980
RC2 · FY2023 · DK
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$633,700
R01 · FY2023 · HL
The role of lamin B1 in normal and myelodysplastic hematopoiesis$573,449
R01 · FY2023 · HL · contact PI
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$636,097
R01 · FY2022 · HL
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$461,320
R01 · FY2021 · HL
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$174,777
R01 · FY2021 · HL
Functional and molecular basis of ineffective erythropoiesis in SF3B1-mutant myelodysplastic syndromes$654,938
R01 · FY2020 · HL
Autologous red blood cells for transfusion in sickle cell disease$194,375
R21 · FY2019 · HL · contact PI
Uncovering epigenetic barriers to hematopoietic stem cell formation$2,332,500
DP2 · FY2018 · HL · contact PI
Hematopoietic stem cells from human pluripotent stem cells and modeling of blood disorders$248,999
R00 · FY2018 · HL · contact PI
Autologous red blood cells for transfusion in sickle cell disease$219,375
R21 · FY2018 · HL · contact PI
Hematopoietic stem cells from human pluripotent stem cells and modeling of blood disorders$249,000
R00 · FY2017 · HL · contact PI
Hematopoietic stem cells from human pluripotent stem cells and modeling of blood disorders$249,000
R00 · FY2016 · HL · contact PI
Hematopoietic stem cells from human pluripotent stem cells and modeling of hemato$131,693
K99 · FY2015 · HL · contact PI
Hematopoietic stem cells from human pluripotent stem cells and modeling of hemato$131,693
K99 · FY2014 · HL · contact PI